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Objective: To evaluate the therapeutic trajectory of intra-articular hyaluronic acid (IAHA) vs placebo for
knee osteoarthritis (OA).
Design: Our data sources include Medline, EMBASE, CINAHL, BIOSIS, Web of Science, Google Scholar,
Cochrane database; hand searched reviews, manuscripts, and, supplements; author contacts for
unpublished data. Randomized trials that reported effects of IAHA vs placebo on knee OA were selected
based on inclusion criteria. We computed effect sizes for change from baseline at 4, 8, 12, 16, 20 and 24
weeks, using Bayesian random effects model. We performed multivariate analyses adjusting for corre-
lation between time points. Meta-regressions were performed adjusting for potential confounders.
Results: The 54 eligible trials included 7545 participants. The conduct and quality of these trials varied in
number of aspects. The effect size (ES) favored IAHA by week 4 (0.31; 95% CI 0.17, 0.45), reaching peak at
week 8 (0.46; 0.28, 0.65), and then trending downwards, with a residual detectable effect at week 24
(0.21; 0.10, 0.31). This therapeutic trajectory was consistent among the subset of high quality trials and
on multivariate analysis adjusting for correlation between time points.
Conclusions: Our meta-analysis highlights a therapeutic trajectory of IAHA for knee OA pain over
6 months post-intervention. With this additional perspective, we are able to infer that IAHA is efﬁcacious
by 4 weeks, reaches its peak effectiveness at 8 weeks and exerts a residual detectable at 24 weeks. On the
other hand, the peak effect size (0.46; 0.28, 0.65), is greater than published effects from other OA
analgesics [acetaminophen (ES¼ 0.13; 0.04, 0.22); NSAIDs (ES¼ 0.29; 0.22, 0.35); COX-2 inhibitors
(ES¼ 0.44; 0.33, 0.55)]. An effect size above 0.20 is considered to be clinically relevant on an individual
patient basis in chronic pain conditions such as knee OA. Thus, its properties could have utility for certain
clinical situations, or in combination with other therapies.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Intra-articular injections of synthetic hyaluronic acid are widely
employed in the medical management of knee osteoarthritis (OA)
pain, based on potentially therapeutic physicochemical proper-
ties1e3. A range of hyaluronic acid products are now available, on
which expenditure in the US is estimated at $725million each year4.
The therapeutic justiﬁcation of the expense of hyaluronic acid
injections rests heavily on the duration of effect, which is claimed to
be prolonged5e8.imothy E. McAlindon, Center
enter, Tufts University School
, MA 02111, USA. Tel: 1-617-
g (T.E. McAlindon).
s Research Society International. PHowever, despite many clinical trials of hyaluronic acid, there
remains contention regarding the efﬁcacy of these products, with
markedly discordant interpretations of the collective data
between experts. Among the six meta-analyses performed to
date9e14, two drew positive conclusions9,10, two reported a small
effect11,12, and two refuted any evidence of efﬁcacy on the basis of
low methodological quality13,14. These meta-analyses evaluated
intra-articular hyaluronic acid (IAHA) therapy from the perspec-
tive of more traditional interventions, generally analyzing two
ﬁxed time points. However, as suggested by a more recent
systematic review comparing hyaluronic acid with intra-articular
corticosteroids15, the beneﬁt of hyaluronic acid appears to be
time-varying. Therefore, evaluation of the post-intervention time
course of the effect of hyaluronic acid (the “therapeutic trajec-
tory”) could provide additional informative perspectives on its
overall efﬁcacy.ublished by Elsevier Ltd. All rights reserved.
Table I
Hierarchy of outcome measures used in the meta-analysis*
Pain:
 Western Ontario and McMaster Universities (WOMAC) OA Index
Pain Subscale (visual analog or Likert version)
 Pain on walking for index joint (visual analog or Likert scale)
 Pain in index joint during activities other than walking
(visual analog or Likert scale)
 Spontaneous pain in index joint (visual analog or Likert scale).
Function:
 WOMAC OA Index Function Subscale (visual analog or Likert version)
 Function score for index joint (visual analog or Likert scale).
Stiffness:
 WOMAC OA Index Stiffness Subscale (visual analog or Likert version)
 Stiffness score for index joint (visual analog or Likert scale).
* To be eligible for our analysis, studies had to report results for at least one of
these outcomes.
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since the last pooled analysis10, and includes new studies of high
methodological rigor7,8,16e20. Therefore, in order to reach a deﬁni-
tive conclusion about the efﬁcacy of hyaluronic acid for knee OA, we
performed an updated meta-analysis evaluating its effect at spec-
iﬁed post-treatment intervals in relation to the minimally clinically
important effect. We also evaluated the potential biases that have
limited interpretation of prior systematic analyses of the pooled
data9e14.
Methods
Search strategy
Two reviewers (RB and NN) independently performed a system-
atic electronic literature search for citations comparing the efﬁcacy
of IAHA injections with placebo in the management of knee OA. We
searched Medline, EMBASE, CINAHL, BIOSIS, Web of Science, Google
scholar and the Cochrane Central Register of Controlled Trials from
inception to March 2010. The key terms (“arthritis” or “osteoar-
thritis” or “osteoarthrosis” or “gonoarthrosis” or “degenerative
arthritis”) and (“viscosupplementation” or “hyaluronic acid” or
“hyaluronan” or “hyaluronate” or “Hyalgan” or “Synvisc” or “Ortho-
visc” or “Artzal” or “Supartz” or “Suplasyn” or “BioHy” or “Euﬂexxa”
or “Nuﬂexxa” or “Hylan GF-20”) were entered as medical subject
heading terms and as text words for searches. All searches were
limited to human randomized clinical trials. No limits were applied
for language, publication date or publication status and foreign
language papers were translated. The last full search was run on
March 3, 2010. We also hand searched the reference lists of all
retrieved studies and conference proceedings of the American
Association of Orthopedic Surgeons, the American College of Rheu-
matology, the British Society for Rheumatology, the European Lea-
gue against Rheumatism, the International League of Associations of
Rheumatology, and the Osteoarthritis Research Society Interna-
tional. The conference proceedingswere searched from January 1990
to February 2010. Product inserts of viscosupplements were con-
sulted. We attempted to identify unpublished data by contacting
experts, study authors and manufacturers. We also contacted the
primary authors of abstracts with incomplete data. The exact full
search strategy is available upon request.
Inclusion & exclusion criteria
We included all clinical trials that were randomized, used human
subjects and compared therapeutic effects of IAHA with placebo to
treat knee OA. To be eligible for inclusion, we required that each trial
report extractable outcome data for at least one measure of pain or
function or stiffness, as currently recommended for OA clinical trials
(Table I).
Outcome measures & time points
Our primary outcome measure was pain reduction at pre-
speciﬁed time points. Since the treatment duration and the post-
treatment assessment time points varied among the trials, a prioriwe
grouped the time points of outcome assessments of individual trials
into seven intervals: 2 weeks (1e2 weeks), 4 weeks (3e6 weeks), 8
weeks (7e10 weeks), 12 weeks (11e14 weeks), 16 weeks (15e18
weeks), 20weeks (19e22weeks) and 24 weeks (23e26weeks). This
groupingwas designed to best capture the data presented in all of the
studies. When an article provided data on more than one pain scale,
we referred to a hierarchy of pain-related outcomes (Table I) and
extracted the outcome that was highest on the list. Our secondary
outcomemeasures were function and stiffness at a pre-speciﬁed endpoint of 8 weeks or 12 weeks or at the end of the trial, whichever
appeared ﬁrst.
Data collection process
We developed a data extraction form, tested it on 10 randomly
selected included studies and reﬁned it accordingly. Two reviewers
(RB and UD) independently, in a blinded manner extracted data
from each trial using this standardized data extraction form. The
data were checked for consistency between the two reviewers. All
disagreements were resolved by consensus. The reviewing team
completed an a priori training exercise and had an inter-rater
agreement of 99.4%. Duplicate publications were carefully checked
and excluded by juxtaposing the author names, treatment
comparisons, sample sizes, outcomes and location of trials.
Data items
Information was extracted from each included trial on:
(1) characteristics of trials (including trial design, number of
participants, withdrawal rate, trial duration, publication status, type
and extent of sponsorship); (2) characteristics of trial participants
(including mean age, sex, stage and severity of disease, duration of
disease); (2) type of intervention (including type, dose, duration and
frequency of hyaluronic acid and placebo); (3) type of outcome
measure (including the level of pain, function and stiffness).
Risk of bias in included trials
Two reviewers (RB and NN) independently, in a blinded manner
and with adequate reliability ascertained the quality of eligible
randomized trials. We determined the adequacy of randomization
(computer generated, centralized randomization), allocation
concealment, blinding of participants, healthcare providers, data
collectors and outcome assessors. We assessed the way all with-
drawn participants were reported and how their data were treated.
The type and extent of sponsorship were also noted.
Each study was evaluated for the type of analysis performed
(intention-to-treat vs noneintention-to-treat). An analysis was
considered to be intention-to-treat if: (1) it was characterized by its
investigators as such and therewas an attempt to analyze data from
all randomized participants, or (2) there were no dropouts (even if
the analysis was not speciﬁcally described as intention-to-treat).
Within each study, the number of participants randomized and
the number analyzed were evaluated. Where possible, data from an
intention-to-treat analysis were extracted.We deﬁned “high quality
trials” as those with more than 100 randomized participants and
Total Screened: 1257 
Excluded: 1117 
Title & Abstract screening  
Duplicates
Full report retrieved: 140 
Excluded: 91 
Other Comparators: 51 
Non RCT’s: 15 
Duplicates & Other Reports: 25
Total eligible reports: 49 (includes 54 trials) 
Trials included in Pain analysis: 49 
Trials included in Function analysis: 16 
Trials included in Stiffness analysis: 15
Fig. 1. Study ﬂow chart.
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allocation concealment.
Statistical methods
We computed an effect size for each study at each time point
separately using Hedges’ g statistic21 corrected for small samples as
follows:
g ¼
h
ðMHA MPLÞ=Spooled
i
Spooled ¼ sqrt
nh
ðnHA1ÞS2HAþðnPL1ÞS2PL
i.
ðnHAþnPL2Þ
o
Corrected Hedges’s g ¼ g ½1 3=f4ðnHA þ nPLÞ  9g
MHA, SHA and nHA are the mean change, standard deviation and
number of participants studied from baseline to a given time point
in the hyaluronic acid group. MPL, SPL and nPL are the corresponding
values in the placebo group. Negative g values favor placebo and
positive g values favor hyaluronic acid.
Three studies22e24, compared placebo with two formulations of
hyaluronic acid and one study18 compared placebo with three
formulations. We treated these as separate trials and compared
outcomes from each formulation with those of the placebo group.
To adjust for the within-study correlation induced by the common
placebo group, we apportioned the control group into as many
equal-sized groups as treatments studied and compared the
treatment to the divided control group.
We calculated the pooled effect sizes using Bayesian random
effects models25. This model incorporates within and between-
study variances and uncertainty in the between-study variance,
which is slightly more conservative (wider uncertainty intervals)
than non-Bayesian random effects models. The study pain scores
were assumed to be randomly drawn from a normal distribution
with mean equal to the overall treatment effect and a variance
representing the heterogeneity between the study means. The
random effect mean and variancewere given non-informative prior
distributions, speciﬁcally N(0, 1000000) for the mean and
Uniform(0,100) for the standard deviation. For the meta-regression
models, the mean was represented as a linear regression function
with both intercept and slope given N(0,1000000) prior distribu-
tions. To compute the Bayesian estimates, we used Markov chain
Monte Carlo implement through the BRugs package running
OpenBUGS within the R statistical software. To check convergence
of the Markov chains, we ran three parallel chains and monitored
convergence with the Gelman-Rubin diagnostic using a between to
within ratio of 1.126. On convergence, which generally occurred
within 1000 runs, we saved 15,000 samples from each chain to
estimate posterior distributions of model parameters.
The pooled data are presented as Forest plots with Bayesian 95%
conﬁdence intervals (CIs). We assessed statistical heterogeneity
with the help of the I2 statistic, which describes the percentage of
total variation across the trials that is attributable to chance27. I2
values of 25%, 50% and 75% correspond to low, moderate, and high
between-trial heterogeneity.
We performed two types of analyses. First, we meta-analyzed
overall pain, function and stiffness as well as pain at each time
point separately. Second, to incorporate the correlation induced by
the multiple measurements at different time points within the
same study we used a multivariate longitudinal regression model
that adjusted for time28.
Where necessary, means and measures of dispersion were
approximated from theﬁgures in themanuscripts.When a published
study only reported the median, range and size of the trial29, weestimated their means and variances according to a published
method30.Wherever necessary, we imputed the standard deviation
according to a published method31.Of note is that one can only
accurately estimate the CIs around change scores when the raw data
are presented in all relevant articles orwhen the correlation between
pre- andpost-test scores is known.Neither quantitywas published in
some of the available studies, so we used a correlation of 0.5 to
calculate the measure of the change score dispersion. In a sensitivity
analysiswe tried other correlations (0.4, 0.6, and 0.7) and they did not
change the result.
For the secondary outcomes of stiffness and function, as well as
to obtain an overall effect of pain, we calculated an overall effect
size at the earliest pre-speciﬁed end point of 8 weeks or 12 weeks
or the end of the trial. This reﬂects the expert consensus opinions,
existing literature10,15 and the manufacturers’ recommendations of
the peak effect of hyaluronic acid. We also estimated the 95%
prediction interval for overall pain.
Using meta-regression, we performed sensitivity analyses to
examine how trial quality, allocation concealment, intention-to-
treat analysis, blinding methodology, trial size, publication status,
publication date, molecular weight and origin of hyaluronic acid
preparation modiﬁed the treatment effect for overall pain. Each
meta-regression used a random effects model32 and examined one
variable at a time.
Results
Trial selection
We identiﬁed 1257 references in our literature search, of which
1117 were excluded after title and abstract screening and removing
duplicates (Fig. 1). Full reports were retrieved for 140 studies for
detailed evaluation. Forty-nine reports describing 54 trials met our
inclusion criteria and were included in the meta-
analysis5e8,16e20,22e24,29,33e67.
Trial characteristics
The 54 trials in the meta-analysis were published between 1983
and 2009 and randomized 7545 participants. Forty-nine trials
(6962 participants) contributed to the meta-analysis of pain-
related outcomes; 16 trials (2571 participants) of function-related
outcomes; and 15 trials (2488 participants) of stiffness-related
outcomes contributed to the meta-analysis. The average age of
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between 28% and 100% of participants. Participant samples
included in trials were heterogeneous with respect to age, sex, knee
radiographic grade, and baseline pain, reﬂecting varied patient
selection among the trials.
Risk of bias within trials
The conduct and quality of the 54 randomized trials varied in
a number of aspects (Table II). The sample sizes varied between
24 and 586 with a mean of 140; 19 trials had a sample size less than
100. Trial duration ranged from 4 to 52 weeks with a mean of
23 weeks; 15 were fewer than 10 weeks duration. AllocationTable II
Risk of bias indicators of included trials
Author Year Groups comparable
at baseline
Adequate allocation
concealment
Shichikawa et al.33 Yes Yes
Shichikawa et al.34 Yes Yes
Bragantini et al.35 No No
Grecomoro et al.36 NR No
Dixon et al.37 No No
Russell et al.38 NA No
Dougados et al.39 No No
Moreland et al.40 NR Yes
Puhl et al.41 No Yes
Cohen et al.42 Yes No
Creamer et al.43 Yes No
Dahlberg et al.29 Yes Yes
Henderson et al.44 Yes No
Scale et al.45 Yes Yes
Carrabba et al.46 Yes No
Corrado et al.47 Yes No
France 1995 Yes Yes
Sala and Miguel49 Unclear Yes
Guler et al.50 NA No
Lohmander et al.51 Yes Yes
UK 1996 NA Yes
Wu et al.52 Yes No
Altman and Moskowitz53 Yes No
Wobig et al.5 No Yes
Hizmetli et al.54 NA No
Huskisson and Donnelly6 Yes No
Brandt et al.55 Yes Yes
Bunyaratavej et al.56 Yes No
Dickson et al.57 Yes Yes
Tamir et al.58 Yes No
Karlsson et al.22 Yes Yes
Karlsson et al.22 Yes Yes
Petrella et al.59 Yes Yes
Jubb et al60 Yes No
Tsai et al.61 NA No
Altman et al.62 Yes Yes
Day et al.63 Yes Yes
Pham et al.64 Yes Yes
Cubukcu et al.65 Yes No
Neustadt et al.66 Yes Yes
Rolf et al.23 Yes No
Rolf et al.23 Yes No
Sezgin et al.67 Yes No
Kotevoglu et al.24 Yes No
Kotevoglu et al.24 Yes No
Petrella and Petrella16 Yes Yes
Lundsgaard et al.17 Yes Yes
Petrella et al.18 Yes Yes
Petrella et al.18 Yes Yes
Petrella et al.18 Yes Yes
Altman et al.7 Yes Yes
Baltzer et al.19 Yes No
Chevalier et al.8 Yes Yes
Baraf et al.20 Yes Yes
NA: not available; NR: not reported.
* Numbers for separate groups were not reported.concealment was adequate in 28 trials (52%); and was either
unclear or not reported in 26 trials (48%). Intention-to-treat anal-
ysis results were reported in 28 trials (52%); 26 trials (48%) reported
per protocol analyses or the analytical approach was either unclear
or not reported. Double blinding was adequate and clearly reported
in 38 trials (70%); 16 trials were single blind/unclear/not reporting.
Dropout rates or losses to follow-up ranged from 0% to 50% with 11
trials reporting 20% or greater loss to follow-up. Sixteen trials (30%)
met our criteria for high quality trials.
Power calculations were reported in 30 trials (56%). Mean
sample size in these trials was 210 compared to 62 in 16 trials
without those calculations in the published manuscripts. Industry
involvement was reported in 53 trials (98%) either in the form ofAdequate double
blinding
Intention-to-treat
analysis
Dropout (percent)
HA Placebo
Yes No 7.7 9.1
Yes No 15.8 10.5
No No 0 5.3
Unclear No 0 10
Yes No 16.7 15.2
No No 19.0*
No No 10.9 16.4
Yes Yes 4.3 6.3
Yes No 6.9 6.5
Yes No 5.1*
No Yes 0 0
Yes Yes 7.1 8.3
Yes No 11.1 4.3
Yes No NR NR
Unclear Yes 0 0
Unclear No 9.5 15.8
Yes Yes 10.3 15.0
Unclear Yes 0 0
Yes NA NR NR
Yes No 20.0 22.5
Yes Yes NR NR
Unclear No 48.4 51.9
Yes No 35.6 32.3
Yes Yes 1.8 1.7
Yes No 20 20
Yes Yes 20 18
Yes No 20.2 25.0
Yes Yes NR NR
Yes Yes 18.9 14.0
No No 20.0 29.2
Yes No 28.2 27.3
Yes No 20.5 27.3
Yes Yes 16.7 6.7
Yes Yes 23.1 20.5
Yes Yes NR NR
Yes Yes 23.1 20.1
Yes Yes 16.4 16.1
Yes Yes 6.9 5.9
No Yes 0 0
Yes No 7.0 12.2
Yes Yes 6.0 12
Yes Yes 8.0 12
No Yes 0 0
Unclear No 23.1 30.7
Unclear No 19.2 30.7
Yes Yes 7.5 7.5
Yes Yes 2.4 4.8
Yes Yes 8.0 6.0
Yes Yes 2.0 6.0
Yes Yes 4.0 6.0
Yes Yes 11.5 11.6
Unclear Yes 11.1 7.5
Yes Yes 7.3 9.3
Yes Yes 7.3 10.2
Table III
Pooled effect sizes (95% CI) for pain
Week All trials High quality trials
N Effect size I2 (%) N Effect size I2 (%)
4 44 0.31 (0.17,0.45) 75 14 0.27 (0.04,0.49) 75
8 26 0.46 (0.28,0.65) 75 7 0.34 (0.02,0.67) 83
12 31 0.25 (0.15,0.36) 60 12 0.29 (0.13,0.45) 75
16 15 0.20 (0.11,0.30) 7 8 0.22 (0.09,0.36) 0
24 20 0.21 (0.10,0.31) 32 6 0.20 (0.03,0.37) 56
N¼Number of trials, I2¼Heterogeneity score.
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member as a co-author.
Forty-ﬁve trials (83%) were published as full-text journal articles,
ﬁve trials were published as abstracts only38,40,42,50,61, and three
were unpublished48,54.One recent trial was reported as an abstract20,
which we expect to see as full-text publication in the near future. In
addition, an unpublished and unreported trial (382 participants) was
identiﬁed in the Orthovisc package insert as OAK 9801. Trials not
published in full-text comprise approximately 18% (1345) of the total
participant population. Only two non-English manuscripts met the
inclusion criteria and were translated33,34.
In summary, trial characteristics including study quality, sample
size and power calculations, duration of the trial, use of intention-
to-treat analysis, losses to follow-up, and industry involvement,
vary substantially. The known extent of unpublished data includes
a large number of individuals.
Heterogeneity
Primary analysis for pain exhibited heterogeneity (I2) scores of
75% at 4 weeks, 75% at 8 weeks, 59% at 12 weeks, 15% at 16 weeks,
zero at 20 weeks and 33% at 24 weeks. The heterogeneity (I2) score
for overall effect size for pain was 70%.Fig. 2. Graph depicting the effeEffects on joint pain
Forty-nine trials (6962 participants) contributed to the meta-
analysis of pain-related outcomes (Table III). The effect size
favored hyaluronic acid byweek 4 (0.31; 95% CI 0.17, 0.45), reaching
a peak at week 8 (0.46; 95% CI 0.28, 0.65), and then trending
downwards, with a residual detectable effect at week 24 (0.21; 95%
CI 0.10, 0.31) [Fig. 2 and Web Fig. 1(AeD)]. This therapeutic
trajectory was consistent among the subset of high quality trials
(2570 participants) and on multivariate analysis adjusting for
correlation between time points.Sensitivity analyses
Table IV presents meta-regression results for pain based on
quality measures. Estimates of effect sizes varied to some degree
depending on trial quality, allocation concealment, intention-to-
treat analysis, blinding methodology, trial size, publication status,
year of publication, molecular weight, and origin of hyaluronic acid
preparation. Most signiﬁcant differences were observed in alloca-
tion concealment (adequate vs inadequate 0.29 vs 0.41); double
blinding (adequate vs inadequate 0.27 vs 0.53); trial size (>100 vs
<100 0.25 vs 0.58) molecular weight (low vs high 0.29 vs 0.60). The
95% prediction interval for overall pain is estimated to be
(0.31, þ0.99).Effects on joint function
The paucity of data at each time point precluded evaluation of the
therapeutic trajectory for joint function and stiffness. Sixteen trials
(2571 participants) contributed to the meta-analysis of function-
related outcomes. The effect size was 0.31 (0.11, 0.51) with hetero-
geneity score (I2) of 79% indicating high heterogeneity among the
trials. But when two outliers (Cubuku et al., and Sezgin et al.) werect sizes (95% CI) for pain.
Table IV
Meta-regression results for overall pain based on trial quality indicators
Variable Total
trials
Randomized, n Effect size
(95% CI)
I2%
All trials 49 6962 0.34 (0.22, 0.46) 70
Trial quality
High 15 2945 0.31 (0.12, 0.51) 74
Low 34 4017 0.35 (0.21, 0.50) 69
Allocation concealment
Adequate 27 4679 0.29 (0.15, 0.44) 66
Unclear/no 22 2283 0.41 (0.23, 0.59) 75
Intent-to-treat analysis
Yes 25 4195 0.31 (0.15, 0.49) 72
No 24 2767 0.35 (0.21, 0.51) 69
Double blinding
Adequate 35 6063 0.27 (0.15, 0.40) 68
Unclear/no/single 14 899 0.53 (0.31, 0.76) 73
Trial size
>100 Participants 32 6207 0.25 (0.13, 0.38) 60
<100 Participants 17 755 0.58 (0.36, 0.80) 77
Publication status
Published 44 6310 0.35 (0.23, 0.48) 72
Unpublished 5 652 0.23 (0.12, 0.57) 35
Year of publication
After 2000 26 4492 0.28 (0.18, 0.38) 58
Before 2000 23 2470 0.37 (0.18, 0.56) 78
Molecular weight*
<1000 KDa 28 3500 0.29 (0.14, 0.44) 61
1000e6000 KDa 10 1859 0.29 (0.06, 0.56) 59
>6000 KDa 9 881 0.60 (0.33, 0.88) 82
Origin of hyaluronic acidy
Avian 42 5598 0.36 (0.23, 0.49) 71
Non-avian 6 1364 0.17 (0.13, 0.49) 59
Note: these ES were calculated at a pre-speciﬁed end point of 8 weeks or 12 weeks
or end of the trial whichever occurred earlier.
* Altman et al. 2004 and Baraf et al. 2009 didn’t report the molecular weight of
hyaluronic acid used.
y Baraf et al. 2009 didn’t report the origin of hyaluronic acid used.
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the heterogeneity score (I2) was reduced to 58%. The pooled effect
size of the ﬁve high quality trials (1536 participants) was 0.12 (0.04,
0.27) showing no effect and the I2 score was 51%. The effect magni-
tude in high quality trials was 76% less than in low quality trials. We
attempted to present the therapeutic trajectories for function and
stiffness with the available data (Web Fig. 2; Web Table I).
Effects on joint stiffness
Fifteen trials (2488 participants) contributed to the meta-
analysis of stiffness-related outcomes. The effect size was 0.31
(0.12, 0.49) favoring hyaluronic acid, with an I2 score of 74%. The
pooled effect size of the four high quality trials (1283 participants)
was 0.10 (0.11, 0.31) showing no effect and the I2 score was 67%.
The effect magnitude in high quality trials was 78% less than in low
quality trials.
Discussion
This meta-analysis highlights the therapeutic trajectory of IAHA
for knee OA pain over 6 months following the intervention. With
this additional perspective, we are able to infer that IAHA is efﬁ-
cacious by 4 weeks, reaches its peak effectiveness at 8 weeks and
exerts a residual detectable at 24 weeks (Fig. 2). On the other hand,
the peak effect size (0.46; 0.28, 0.65), is greater than published
effects from other OA analgesics. In fact, in comparison toacetaminophen (ES¼ 0.13; 0.04, 0.22) this is up to four times
better68; also appears to be better than NSAIDs (ES¼ 0.29;
0.22,0.35)69 and equivalent to COX-2 inhibitors (ES¼ 0.44;
0.33,0.55)70. According to the IMMPACT consensus71, an effect size
above 0.20 is considered to be clinically relevant on an individual
patient basis in chronic pain conditions such as knee OA. The effect
sizes in our pooled analyses were above this level from weeks 4 to
24 but were subsequently close to, or at that threshold at some time
points.
One unique aspect of this meta-analysis is that we examined
the therapeutic response over time by pooling the data for each
time point separately. The product of this analysis was infor-
mative in laying out the pattern of therapeutic response attrib-
utable to the intervention. However, two limitations to this
approach are that not all trials provided data for each of the time
points, and the possibility of correlations among outcomes
between time points. We addressed these issues by running
a multivariate longitudinal regression model that adjusted for
time.
We attempted to minimize publication bias by employing
a broad search strategy independently by different reviewers and
making author contacts wherever possible. We included eight
unpublished trials in our analysis in order to minimize publication
bias. We improved reliability on risk of bias assessment and data
extraction as two reviewers performed procedures independently
before consensus was obtained. We minimized bias through study
design and quality by doing sensitivity analyses based on study
design and gave an overview of risk of bias assessment.
Another problem in attempting to pool study results was the
considerable variety of assessment instruments. To address this, we
generated effect sizes by computing Hedges g statistic. Effect sizes
provide unit less measures of treatment efﬁcacy centered at zero
effect21. Bias in clinical trial reports can also theoretically occur
from post-hoc selection of the outcomemeasures favoring the study
intervention. We tried to reduce this from biasing our pooled
estimates by using a hierarchy of recommended outcomes to
determine which measure to employ as the index outcome
(Table I).
One other limitation this kind of review suffers is from pooling
several hyaluronic acid agents which differ in many characteristics
including molecular weights, origin, viscosity, cross-linking etc.
We addressed this issue by performing several sensitivity analyses
wherever possible. We didn’t attempt to do sensitivity analyses
based on viscosity or cross-linking since that might bias our
review as a direct comparison between different agents. Our
attempt to do sensitivity analyses based on differing selection
criteria speciﬁcally knee effusionwas not successful mainly due to
paucity of data.
The placebo effect size in OA trials tends to be large compared
to untreated baseline especially in those involving intra-articular
injections72. Also, there is theoretical possibility that intra-
articular saline could have a therapeutic effect to that may be
sustained for 6 months or more73e75. Furthermore, a therapeutic
effect of aspiration of synovial ﬂuid could contribute to
a response in patients receiving placebo. We would expect all
these factors to bias treatment group differences to the null, in
which case our effect size would underestimate the clinical
beneﬁt.
In summary, using a pooled analysis that accommodates its
post-administration trajectory of effect, we conﬁrm IAHA has efﬁ-
cacy for knee OA pain. The magnitude of effect is modest, and
exceeds a minimally clinically signiﬁcant threshold. Thus, its
properties could have utility for certain clinical situations, or in
combination with other therapies. These data should predicate
a re-evaluation of its overall cost-utility.
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